1. Home
  2. FULC vs ELA Comparison

FULC vs ELA Comparison

Compare FULC & ELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FULC
  • ELA
  • Stock Information
  • Founded
  • FULC 2015
  • ELA 1965
  • Country
  • FULC United States
  • ELA United States
  • Employees
  • FULC N/A
  • ELA N/A
  • Industry
  • FULC Biotechnology: Pharmaceutical Preparations
  • ELA Consumer Specialties
  • Sector
  • FULC Health Care
  • ELA Consumer Discretionary
  • Exchange
  • FULC Nasdaq
  • ELA Nasdaq
  • Market Cap
  • FULC 210.9M
  • ELA 175.2M
  • IPO Year
  • FULC 2019
  • ELA N/A
  • Fundamental
  • Price
  • FULC $2.90
  • ELA $6.26
  • Analyst Decision
  • FULC Hold
  • ELA Strong Buy
  • Analyst Count
  • FULC 8
  • ELA 1
  • Target Price
  • FULC $6.57
  • ELA $7.00
  • AVG Volume (30 Days)
  • FULC 427.9K
  • ELA 21.1K
  • Earning Date
  • FULC 05-12-2025
  • ELA 03-26-2025
  • Dividend Yield
  • FULC N/A
  • ELA N/A
  • EPS Growth
  • FULC N/A
  • ELA N/A
  • EPS
  • FULC N/A
  • ELA 0.26
  • Revenue
  • FULC $80,000,000.00
  • ELA $180,376,229.00
  • Revenue This Year
  • FULC N/A
  • ELA $1.61
  • Revenue Next Year
  • FULC N/A
  • ELA $6.30
  • P/E Ratio
  • FULC N/A
  • ELA $23.94
  • Revenue Growth
  • FULC 2752.05
  • ELA 2.92
  • 52 Week Low
  • FULC $2.78
  • ELA $4.20
  • 52 Week High
  • FULC $10.13
  • ELA $7.88
  • Technical
  • Relative Strength Index (RSI)
  • FULC 37.74
  • ELA 54.73
  • Support Level
  • FULC $3.00
  • ELA $5.43
  • Resistance Level
  • FULC $3.35
  • ELA $6.66
  • Average True Range (ATR)
  • FULC 0.18
  • ELA 0.27
  • MACD
  • FULC 0.02
  • ELA 0.15
  • Stochastic Oscillator
  • FULC 24.78
  • ELA 70.83

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

About ELA Envela Corporation

Envela Corp and its subsidiaries engage in diverse business activities within the recommerce sector. These include re-commercializing luxury hard assets, consumer electronics and IT equipment; and end-of-life recycling solutions. It operates through two segments, Consumer, and Commercial Services. The Consumer segment which generates key revenue for the company predominantly buys to resell or recycle luxury hard assets like jewelry, diamonds, gemstones, fine watches, rare coins and related collectibles, precious-metal bullion products, gold, silver, and other precious metals. The Commercial Services segment provides asset-disposition solutions to government agencies, middle-market firms, corporations, and other organizations.

Share on Social Networks: